Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 2,358 Shares of Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Timothy Rolph sold 2,358 shares of the business's stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $54.00, for a total value of $127,332.00. Following the completion of the sale, the insider now owns 167,363 shares in the company, valued at approximately $9,037,602. This trade represents a 1.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Timothy Rolph also recently made the following trade(s):

• On Thursday, June 5th, Timothy Rolph sold 12,500 shares of Akero Therapeutics stock. The shares were sold at an average price of $53.49, for a total value of $668,625.00.
• On Friday, June 6th, Timothy Rolph sold 25,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $55.04, for a total value of $1,376,000.00.
• On Tuesday, May 6th, Timothy Rolph sold 12,500 shares of Akero Therapeutics stock. The shares were sold at an average price of $43.43, for a total value of $542,875.00.
• On Thursday, April 24th, Timothy Rolph sold 6,250 shares of Akero Therapeutics stock. The shares were sold at an average price of $41.03, for a total value of $256,437.50.
• On Monday, April 7th, Timothy Rolph sold 6,250 shares of Akero Therapeutics stock. The shares were sold at an average price of $35.88, for a total value of $224,250.00.

Akero Therapeutics Stock Performance

Shares of NASDAQ:AKRO traded up $2.06 during trading on Friday, reaching $55.62. 2,224,332 shares of the stock were exchanged, compared to its average volume of 1,009,425. Akero Therapeutics, Inc. has a 12 month low of $21.02 and a 12 month high of $58.40. The firm has a market cap of $4.43 billion, a PE ratio of -14.83 and a beta of -0.16. The stock has a 50-day moving average price of $43.96 and a 200-day moving average price of $40.36. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported $0.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.01) by $1.91. Research analysts expect that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

Wall Street Analyst Weigh In

AKRO has been the topic of a number of recent research reports. HC Wainwright lifted their target price on Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research report on Monday, March 3rd. Morgan Stanley reaffirmed an "overweight" rating on shares of Akero Therapeutics in a research report on Sunday, March 2nd. Citigroup lowered their target price on Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Finally, Bank of America lifted their target price on Akero Therapeutics from $63.00 to $64.00 and gave the company a "buy" rating in a research report on Tuesday, May 27th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $82.50.

Institutional Investors Weigh In On Akero Therapeutics

A number of institutional investors have recently made changes to their positions in the company. Rhumbline Advisers boosted its holdings in shares of Akero Therapeutics by 4.7% during the first quarter. Rhumbline Advisers now owns 110,687 shares of the company's stock worth $4,481,000 after acquiring an additional 5,001 shares during the period. Strs Ohio bought a new stake in shares of Akero Therapeutics in the first quarter valued at approximately $510,000. Intech Investment Management LLC boosted its stake in shares of Akero Therapeutics by 54.4% in the first quarter. Intech Investment Management LLC now owns 58,522 shares of the company's stock valued at $2,369,000 after buying an additional 20,620 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Akero Therapeutics by 53.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 109,909 shares of the company's stock valued at $4,449,000 after buying an additional 38,458 shares during the period. Finally, Woodline Partners LP boosted its stake in shares of Akero Therapeutics by 26.5% in the first quarter. Woodline Partners LP now owns 480,736 shares of the company's stock valued at $19,460,000 after buying an additional 100,769 shares during the period.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.